Keyphrases
Clopidogrel
94%
Dutch Pharmacogenetics Working Group
69%
Popular
63%
Ticagrelor
49%
Pharmacogenetics
48%
Drug-gene Interaction
43%
CYP2C19
42%
CYP2C19 Polymorphism
36%
Cytochrome P450 2D6 (CYP2D6)
36%
Genotype
31%
Genetic Variants
30%
Pharmacist
28%
Sarcoidosis
28%
Pharmacogenomics
26%
Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS)
23%
Morbidly Obese Patients
22%
Prasugrel
21%
Confidence Interval
21%
Clinical Decision-making
21%
Major Bleeding
20%
Community-acquired Pneumonia
20%
P2Y12 Inhibitors
19%
Antiplatelet Therapy
19%
Propofol
19%
Pharmacokinetics
18%
Genotype-guided
18%
Elderly Patients
18%
Aspirin
17%
Acute Coronary Syndrome
16%
Platelet Reactivity
15%
Pneumonia
15%
Europe
15%
Flecainide
14%
Infliximab
14%
Primary Percutaneous Coronary Intervention
13%
Tramadol
12%
Intermediate Metabolizers
12%
High On-treatment Platelet Reactivity
12%
CYP2C9
12%
Cost-effectiveness
12%
Bleeding Events
12%
Platelet Inhibition
12%
Irinotecan
12%
Codeine
12%
Clinical Outcomes
12%
Sotalol
11%
Randomized Controlled Trial
11%
Netherlands
11%
Pharmacodynamics
11%
Progeny Trial
11%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacogenetics
100%
Clopidogrel
93%
Ticagrelor
52%
CYP2C19
47%
Drug Interaction
40%
Bleeding
39%
CYP2D6
37%
Acute Coronary Syndrome
30%
Pharmacokinetics
28%
Prasugrel
27%
Sarcoidosis
24%
Antiplatelet
23%
Acetylsalicylic Acid
22%
Community Acquired Pneumonia
20%
Pharmacogenomics
19%
Non Small Cell Lung Cancer
19%
Heart Infarction
18%
Placebo
18%
Pharmacodynamics
17%
Chemotherapy
16%
Pharmacy Practice
15%
Flecainide
14%
Propofol
14%
Pharmacotherapy
13%
Tramadol
12%
Randomized Controlled Trial
12%
Sotalol
11%
Stent Thrombosis
11%
Anticoagulant Agent
11%
Infliximab
11%
Side Effect
11%
CYP3A4
11%
Adenosine Diphosphate
10%
CYP2C9
10%
Abacavir
10%
Normal Human
10%
Adverse Drug Reaction
10%
Irinotecan
10%
Codeine
10%
Antiarrhythmic Agent
10%
Tumor Necrosis Factor
9%
Cerebrovascular Accident
9%
Oxycodone
9%
Cefazolin
9%
ST Segment Elevation Myocardial Infarction
9%
Selective Serotonin Reuptake Inhibitor
9%
Sulfonylurea
9%
Fibrinogen Receptor
8%
SLCO1B1
8%
Coumarin Derivative
8%